Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Is Jumping Today

By Keith Speights - May 3, 2021 at 12:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's COVID-19 vaccine could be on a fast track to win authorization in India.

What happened

Shares of BioNTech (BNTX 2.24%) were jumping 10.6% higher as of 12:23 p.m. EDT on Monday. The big gain came after Pfizer (PFE -1.28%) stated that it's in discussions with the government of India about accelerating authorization of the partners' COVID-19 vaccine. 

So what

Pfizer CEO Albert Bourla stated on Monday, "We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country." Although Pfizer and BioNTech submitted the COVID-19 vaccine for Emergency Use Authorization (EUA) in India in late 2020, the Indian government's requirement of a safety study conducted in the country prompted the two drugmakers to withdraw the application in February.

Gloved hand holding a syringe with a needle next to a coronavirus vaccine vial in front of an Indian flag

Image source: Getty Images.

However, India is now reeling from a surge in COVID-19 cases. The country indicated that it would change its authorization process for vaccines to require a local clinical trial within 30 days after approval instead of prior to approval.

The country presents a large market opportunity for Pfizer and BioNTech. However, the relatively high price tag for the companies' COVID-19 vaccine combined with its storage requirements could limit those prospects to some extent.

Now what

BioNTech is enjoying considerable success in 2021 with the biotech stock soaring more than 150% year to date after today's gain. It could still have other catalysts on the way, including the potential for its COVID-19 vaccine winning EUA in India and the possibility of securing additional large supply deals outside of the U.S.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$161.03 (2.24%) $3.53
Pfizer Inc. Stock Quote
Pfizer Inc.
$51.64 (-1.28%) $0.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.